Shanghai Yizhong Pharmaceutical Co Ltd
医疗健康 · 专科与仿制药
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.
MARKET 市值 8.87B CNY PE 126.2x
52W ¥37.94 – ¥83.6
EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG — 营收 YoY 11.4%
▲ ROE 4.8% 营业利润率 15.6% 净利润率 21.1%